CME Group Inc. (NASDAQ:CME) had its price target increased by Deutsche Bank AG from $115.00 to $116.00 in a research report sent to investors on Wednesday. Deutsche Bank AG currently has a buy rating on the stock.
CME has been the subject of several other reports. Jefferies Group lifted their target price on CME Group from $112.00 to $118.00 and gave the stock a buy rating in a research note on Wednesday, August 31st. JPMorgan Chase & Co. set a $116.00 target price on CME Group and gave the stock a buy rating in a research note on Monday, September 12th. Zacks Investment Research upgraded CME Group from a sell rating to a hold rating in a research note on Thursday, June 30th. Barclays PLC reduced their target price on CME Group from $100.00 to $99.00 and set an equal weight rating for the company in a research note on Friday, July 29th. Finally, Keefe, Bruyette & Woods boosted their price target on CME Group from $99.00 to $103.00 and gave the company a market perform rating in a research note on Friday, July 29th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of $103.27.
Shares of CME Group (NASDAQ:CME) opened at 104.11 on Wednesday. The firm has a market capitalization of $35.28 billion, a price-to-earnings ratio of 26.29 and a beta of 0.83. CME Group has a 52 week low of $81.87 and a 52 week high of $110.35. The stock has a 50 day moving average price of $106.65 and a 200-day moving average price of $99.53.
CME Group (NASDAQ:CME) last issued its earnings results on Thursday, July 28th. The company reported $1.14 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.11 by $0.03. CME Group had a return on equity of 6.83% and a net margin of 38.22%. The company earned $906 million during the quarter, compared to the consensus estimate of $897.84 million. During the same period in the previous year, the company posted $0.95 EPS. The firm’s revenue for the quarter was up 10.5% compared to the same quarter last year. On average, equities research analysts forecast that CME Group will post $4.43 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 26th. Investors of record on Friday, September 9th were given a dividend of $0.60 per share. The ex-dividend date was Wednesday, September 7th. This represents a $2.40 annualized dividend and a dividend yield of 2.31%. CME Group’s dividend payout ratio is currently 60.61%.
In related news, Director Ronald A. Pankau sold 400 shares of the company’s stock in a transaction on Thursday, August 11th. The stock was sold at an average price of $103.32, for a total transaction of $41,328.00. Following the completion of the sale, the director now directly owns 4,382 shares in the company, valued at approximately $452,748.24. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Martin J. Gepsman sold 300 shares of the company’s stock in a transaction on Friday, September 2nd. The stock was sold at an average price of $109.00, for a total value of $32,700.00. Following the sale, the director now owns 42,802 shares of the company’s stock, valued at $4,665,418. The disclosure for this sale can be found here. Corporate insiders own 0.61% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the stock. Swarthmore Group Inc. purchased a new position in CME Group during the third quarter valued at approximately $19,843,000. Independent Portfolio Consultants Inc. purchased a new position in CME Group during the third quarter valued at approximately $227,000. Hefty Wealth Partners increased its position in CME Group by 11.4% in the third quarter. Hefty Wealth Partners now owns 9,553 shares of the company’s stock valued at $998,000 after buying an additional 980 shares in the last quarter. Cullinan Associates Inc. increased its position in CME Group by 6.7% in the third quarter. Cullinan Associates Inc. now owns 58,655 shares of the company’s stock valued at $6,131,000 after buying an additional 3,705 shares in the last quarter. Finally, Evercore Wealth Management LLC increased its position in CME Group by 19.5% in the second quarter. Evercore Wealth Management LLC now owns 2,270 shares of the company’s stock valued at $221,000 after buying an additional 370 shares in the last quarter. Hedge funds and other institutional investors own 80.29% of the company’s stock.
CME Group Company Profile
CME Group Inc is a provider of products across all major asset classes, based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals. The Company’s products include both exchange-traded and privately negotiated futures and options contracts and swaps. The Company connects buyers and sellers together through its CME Globex electronic trading platform across the globe and its open outcry trading facilities in Chicago and New York City.
Receive News & Ratings for CME Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group Inc. and related companies with MarketBeat.com's FREE daily email newsletter.